Posted on 09/03/2010 in Animal Health Supplier News Pfizer Animal Health has agreed a deal which will see it transfer a number of its assets to fellow healthcare group Lilly.
The veterinary pharmaceutical company is selling the European rights to several vaccines, parasiticides and feed additives to Lilly's animal health division Elanco, as part of the terms of its recent acquisition of Wyeth.
As a result, Lilly will also take control of one of Pfizer Animal Health's manufacturing facilities in Sligo, Ireland, with all staff set to be offered positions at Lilly.
In return, Pfizer will receive an undisclosed upfront payment, with the closing of this transaction still subject to approval from the appropriate regulatory bodies.
Jeff Simmons, president of Elanco, welcomed the purchase, saying that Pfizer's product portfolio and facility represent "a natural fit for Elanco and positions us well for sustained growth".
Last week, Pfizer Animal Health licensed a vaccine enhancement and delivery developed by Immunovaccine in order to produce a new livestock treatment.Other news stories from 09/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
